Over the years, Indicus has developed several products and is marketing in the US through major US pharmaceutical Companies.
We have submitted 49 applications of which 32 applications got approval from the US FDA by 2023.
Indicus Pharma continues to work on development of 5 to 10 products along with its partners at any time.
Indicus Pharma engages in flexible partnership models with US leading pharmaceutical Companies that share its
values to deliver breakthrough products.
Indicus Pharma was established in 2005 with a goal to develop and market niche generic formulations for the US markets.
It is a subsidiary of USV North America Inc.
The industry is growing with the increased awareness, acceptance of generics and favorable legislation.
Indicus Pharma markets pharmaceutical products primarily developed and manufactured by USV Private
Limited, a Leading Global Pharmaceutical company based in Mumbai, India.
USVís R&D Capabilities revolve around its focus on niche products with cutting edge technologies and global standards of quality.
USV is present worldwide in more than 65+ countries with rich experience in the generic industry.
It is a reliable formulation and API supplier to leading multinational Companies.
USVís facilities manufacture pharmaceutical products under cGMP environment and are:
inspected and approved by various international regulatory agencies, including the USFDA, MHRA, EU, WHO, ANVISA, Health Canada, TGA etc.
capable of handling commercial manufacturing of almost all solid oral products and sterile products
equipped with a state-of-the-art manufacturing infrastructure
managed by team of experienced professionals.